DIA: Driving Insights to Action
Science:Life Sciences
As the Director of CDER's Office of Generic Drugs' Clinical Safety Surveillance Staff, Dr. Howard Chazin leads a multidisciplinary team of pharmacists, medical officers and data analysts to identify and assess emerging complex safety issues related to generic drugs. “Generic drugs provide considerable cost savings. They also enhance the availability of quality medications to the American public,” he explains. “The American public should have confidence in generic drugs.”
Advances and Best Practices in Communications with Consumers and Health Care Professionals
Challenges in Deploying a Global Pharmacovigilance System
Challenges in Adverse Event Reporting and the Role of Specialty Pharmacies
Access & Attitude to Clinical Trial Technology: The Global Investigator Perspective
What Precision Medicine Means Today and Will Mean Tomorrow for Patient Care
FDA Director of Division of Online Communications, CDER, Discusses FDA's First Mobile App
Pediatric Drug Development & Therapeutics in September TIRS
TransCelerate BioPharma Clinical Quality Management System Conceptual Framework
Patient Engagement and Rare Diseases at DIA
Ethical Considerations in Policies on Drug, Device, and Companion Diagnostics Development
Medical Communications Transformation and Impact on Health Care Community
Challenging the Value of Source Data Verification
The Impact of Collaborative and Risk Sharing Innovation Approaches on Clinical and Regulatory Cycle Times
How to Get Published with DIA
Perspectives on Statistics
An Expanded Role for Patients in Clinical Trial Design
Women and Children First—Time for a Coalition to Address a Substantial Patient Need
PhactMI Strives to Bring Medical Information Transparency to the Health Care Community
Clinical Safety and Pharmacovigilance
Innovative Partnering Models and Outsourcing Strategies
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
Terrace | تراس